Ocular toxicity associated with anti-CD20 monoclonal antibodies: A pharmacovigilance analysis using the FAERS database
Anti-CD20 antibodies require careful ocular monitoring, particularly in multiple sclerosis patients. The elevated blepharospasm risks with ofatumumab and dyschromatopsia with rituximab highlights potential CNS-and optic pathway-related effects that warrant further study to improve MS treatment safety.
Authors
- Yun Kuang
- Junlong Ma (ORCID: https://orcid.org/0000-0003-1949-1201)
- Jinlian Xie
- Longjian Huang
- Guoping Yang
- Chengxian Guo
- Yaxin Liu
- Tong Li
- YAN GUO
- Yuxia Xiang
Institutions
- Central South University (CN)
- Hunan Normal University (CN)
- Affiliated Hospital of Youjiang Medical University for Nationalities (CN)
- Third Xiangya Hospital (CN)
Publication Details
- Journal
- Multiple Sclerosis and Related Disorders
- Published
- 2026-03-23
- DOI
- https://doi.org/10.1016/j.msard.2026.107158
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00